Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chan FKL et al. – By providing clinicians with a new, descriptive language for adverse events through the entire GI tract, the CSULGIE endpoint has the potential to become a standard tool for evaluating the GI effects of a range of therapies.

Related Articles

Use of Nonsteroidal Antiinflammatory Drugs and Risk of Endometrial Cancer
American Journal of Epidemiology, 11/09/09    Relevance Score: 78%

Gastrointestinal Safety of Nonsteroidal Antiinflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Patients on Warfarin
Annals of Pharmacotherapy, 10/13/09    Relevance Score: 78%

Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09    Relevance Score: 77%

Effect of nonsteroidal anti-inflammatory drug plasters for knee osteoarthritis in Japanese: a randomized controlled trial
Modern Rheumatology, 10/12/09    Relevance Score: 67%

Celecoxib in arthritis: relative risk management profile and implications for patients
Therapeutics and Clinical Risk Management, 11/10/09    Relevance Score: 66%

Today in Adverse Drug Reactions...keeping you current

Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain
Journal of Orthopaedics and Traumatology, 11/24/09

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
British Journal of Clinical Pharmacology, 11/24/09

Appraising the post-marketing safety of medicines: A description of national and international pharmacovigilance with a focus on medicines used in chronic pain
Current Anaesthesia and Critical Care, 11/24/09

Today in Stomach/GI...keeping you current

Proton Pump Inhibitors and Pain
Pain Physician, 11/25/09

Clinical Features of Gastroduodenal Ulcer in Japanese Patients Taking Low-Dose Aspirin
Digestive Diseases and Sciences, 11/24/09

Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
Cephalon, 11/24/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address